Co-Authors
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and JAMES C YAO.
Connection Strength
1.584
-
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013 Mar 01; 73(5):1449-53.
Score: 0.443
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
Score: 0.415
-
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8.
Score: 0.325
-
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun; 22(3):431-41.
Score: 0.129
-
Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res. 2013 Aug 15; 19(16):4305-8.
Score: 0.114
-
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66.
Score: 0.078
-
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
Score: 0.043
-
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
Score: 0.037